Gilead Sciences

Yahoo Finance • yesterday

ER+/ HER2 - ve Breast Cancer Market Insight, Epidemiology, and Market Forecast Report 2022-2036

Company Logo Opportunities in the ER+/HER2- breast cancer market include the growth of novel CDK4/6 inhibitors and next-generation SERDs, offering advanced treatment options. Strong R&D from players like AstraZeneca and Roche, coupled wit... Full story

Yahoo Finance • 2 days ago

Gilead (GILD), Tempus AI (TEM) Expand Multi-Year Oncology R&D Collaboration

Gilead Sciences Inc. (NASDAQ:GILD) is one of the 8 Best Quality Stocks to Buy According to Hedge Funds. Gilead Sciences Inc. (NASDAQ:GILD) is one of the best quality stocks to buy according to hedge funds. On April 9, Tempus AI (NASDAQ:TEM... Full story

Yahoo Finance • 3 days ago

Gilead price target raised to $175 from $171 at Morgan Stanley

Morgan Stanley raised the firm’s price target on Gilead (GILD) to $175 from $171 and keeps an Overweight rating on the shares. The firm adjusted models among its biopharma coverage for IQVIA trends as well as intra-quarter updates ahead of... Full story

Yahoo Finance • 4 days ago

PLTR, RIVN Gain Favor As INTC Momentum Fades

This article first appeared on GuruFocus. Palantir (NASDAQ:PLTR) and Rivian (NASDAQ:RIVN) are picking up fresh support from analysts, while Intel (NASDAQ:INTC) and Gilead (NASDAQ:GILD) are starting to see a more cautious tone creep in. O... Full story

Yahoo Finance • 5 days ago

Tempus AI Expands Collaboration With Gilead Sciences To Maximize Insights In Oncology Pipeline

(RTTNews) - Healthcare technology company Tempus AI, Inc. (TEM) Thursday announced an expanded, multi-year collaboration with Gilead Sciences, Inc. (GILD) to build and advance its oncology pipeline. As per the expanded agreement, Tempus A... Full story

Yahoo Finance • 5 days ago

Gilead price target raised to $155 from $152 at Truist

Truist analyst Gregory Renza raised the firm’s price target on Gilead (GILD) to $155 from $152 and keeps a Buy rating on the shares as part of a broader research note previewing Q1 earnings in Biotech. Reactivity to regulatory and policy s... Full story

Yahoo Finance • 6 days ago

Gilead Agrees $5 Billion Tubulis Acquisition To Expand Cancer Drug Pipeline

This article first appeared on GuruFocus. Gilead Sciences (NASDAQ:GILD) is leaning further into oncology with a sizable bet on next-generation cancer therapies, agreeing to acquire Germany-based Tubulis GmbH for up to $5 billion. The deal... Full story

Yahoo Finance • 7 days ago

Top Midday Stories: Stocks Fall as US-Iran Ceasefire Hopes Fade; Health Insurance Stocks Rise After Big Medicare Advantage Payment Rate Bump

All three major US stock indexes were down in late-morning trading Tuesday, as President Donald Trum PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 7 days ago

Gilead outlays $5bn to acquire ADC specialist Tubulis

Gilead will acquire antibody-drug conjugate (ADC) developer Tubulis in a deal worth up to $5bn, continuing the big pharma company’s recent string of high-profile M&A activity in 2026. As per the agreement, Gilead will pay $3.15bn upfront... Full story

Yahoo Finance • 7 days ago

EQT Life Sciences to exit minority stake in Tubulis via sale to Gilead Sciences for up to USD 5.0 billion

Gilead Sciences has entered into a definitive agreement to acquire Tubulis, a private Germany-based, clinical-stage biotechnology company EQT Life Sciences led the Series B2 financing of Tubulis in March 2024, and has since suppEQTorted th... Full story

Yahoo Finance • 7 days ago

Gilead to acquire Tubulis GmbH for $5B

[Gilead Sciences, Inc. headquarters in Silicon Valley] Sundry Photography Gilead (GILD [https://seekingalpha.com/symbol/GILD]) said on Tuesday that it would acquire Germany-based biotechnology firm Tubulis GmbH for $5B to build on its onc... Full story

Yahoo Finance • 7 days ago

Gilead to acquire Tubulis GmbH for up to $5 billion

April 7 (Reuters) - Gilead said on Tuesday it would acquire private Germany-based Tubulis GmbH for ‌up to $5 billion, as the U.S. drugmaker ‌looks to boost its pipeline with a lucrative class of ​experimental cancer drugs referred to as "g... Full story

Yahoo Finance • 10 days ago

Galapagos NV (GLPG) Signs Agreement with Gilead on Ouro Medicines Assets

Galapagos NV (NASDAQ:GLPG) is one of the 7 Fastest Growing European Stocks to Invest In. On March 31, 2026, Galapagos NV (NASDAQ:GLPG) announced a binding agreement with Gilead Sciences (NASDAQ:GILD) related to Gilead’s planned acquisitio... Full story

Yahoo Finance • 12 days ago

iShares S&P 100 ETF Experiences Big Outflow

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares S&P 100 ETF (Symbol: OEF) where we have detected an approximate $152.7 million dollar outflow -- that... Full story

Yahoo Finance • 12 days ago

No deal yet? Trump readies new tariffs on select drugmakers - report

[Senior woman buying medicine at drugstore] Luis Alvarez The Trump administration plans to impose tariffs on pharmaceutical companies that haven't agreed to lower U.S. drug prices, with an announcement expected as soon as Thursday, _Bloom... Full story

Yahoo Finance • 13 days ago

Gilead Extends Tender Offer to Acquire Arcellx

FOSTER CITY, Calif., April 01, 2026--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today extended the expiration of the tender offer to purchase all outstanding shares of common stock of Arcellx. The offer remains at a purchase pri... Full story

Yahoo Finance • 13 days ago

AI-linked stocks see surge in ownership breadth, led by Palantir and GE Vernova

[Artificial intelligence circuit board 5] Jonathan Kitchen Stocks tied to artificial intelligence themes have dominated gains in ownership breadth over the past year, underscoring continued investor rotation into the sector, according to... Full story

Yahoo Finance • 14 days ago

Galapagos NV, Gilead Sciences strike deal tied to Ouro Medicines acquisition

Galapagos NV (GLPG [https://seekingalpha.com/symbol/GLPG]) Tuesday said that it has entered into a binding agreement [https://seekingalpha.com/pr/20456224-galapagos-and-gilead-enter-into-binding-agreement-to-collaborate-on-advancing-first-... Full story

Yahoo Finance • 14 days ago

Galapagos and Gilead Enter into Binding Agreement to Collaborate on Advancing First in Class T Cell Engager Program for Autoimmune Diseases

New collaboration structure achieves meaningfully improved financial terms and flexibility for Galapagos Following this transaction, the Company will continue to have a majority of its cash remaining for additional strategic transactions... Full story

Yahoo Finance • 14 days ago

Galapagos en Gilead gaan definitieve overeenkomst aan over samenwerking om een first-in-class T-cel-engagerprogramma voor auto-immuunziekten verder te ontwikkelen

De nieuwe samenwerkingsstructuur levert aanzienlijk verbeterde financiële voorwaarden en flexibiliteit voor Galapagos op Na deze transactie blijft de Vennootschap over het grootste deel van haar liquide middelen beschikken voor bijkomende... Full story